Company news

Niagen Bioscience, Inc. news in 2025

Niagen Bioscience, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

December 21, 2025

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

November 12, 2025

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

November 11, 2025

Niagen Bioscience Announces $10 Million Share Repurchase Program

November 5, 2025

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

November 3, 2025

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 20, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

October 5, 2025

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

September 30, 2025

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

September 16, 2025

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 6, 2025

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 3, 2025

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 22, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

July 13, 2025

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 7, 2025

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

June 19, 2025

Niagen Bioscience to Participate in the BIO 2025 International Convention

June 10, 2025

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

June 8, 2025

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

June 3, 2025

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 6, 2025

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 4, 2025

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

April 28, 2025

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

April 27, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

April 6, 2025

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

March 19, 2025

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

March 10, 2025

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

March 3, 2025

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

February 24, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

January 5, 2025

Calls in 2025

Decks in 2025